We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01240369
Recruitment Status : Unknown
Verified November 2010 by China Medical University Hospital.
Recruitment status was:  Active, not recruiting
First Posted : November 15, 2010
Last Update Posted : November 15, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:

Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer. Clinically, over 80% of patients with cancer were at late stage when they were diagnosed. Therefore, it is important for us to find the biomarker that serve as the early prediction of cancer.

The investigators have published that VEGFC over-expressed in non-small cell lung cancer. VEGFC plays a critical role in regulating motility of tumor cells, promotes proliferation of lymphatic endothelial cells and enhances migration and invasion. Investigator found that VEGFC over-expressed in the serum of esophageal cancer patients. Therefore, it is worthwhile to investigate the correlation between VEGFC, clinical lung cancer and esophageal cancer.

MicroRNAs (miRNAs) are conserved, endogenous, small, and noncoding RNA molecules of 21~23 nucleotides that function as post-transcriptional gene regulators. Recent studies indicated that certain microRNAs reduced in cancer patients. Therefore it is important to investigate whether specific microRNA changed in certain kinds of cancer patients.


Condition or disease
VEGFC Protein in Serum VEGFC Protein in Non Small Cell Lung Cancer VEGFC Protein in ESCC CTTN Protein in ESCC miR326 in ESCC and Non Small Cell Lung Cancer

Study Design

Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Study Start Date : October 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
VEGF-C low
VEGF-C high
miR-326 low
miR-326 high


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
ESCC and NSCLC patients
Criteria

Inclusion Criteria:

  • tumor size > 0.5 cm3

Exclusion Criteria:

  • tumor size < 0.5 cm3
More Information

Responsible Party: Jen-Liang Su, China Medical University Hospital
ClinicalTrials.gov Identifier: NCT01240369     History of Changes
Other Study ID Numbers: DMR99-IRB-206
First Posted: November 15, 2010    Key Record Dates
Last Update Posted: November 15, 2010
Last Verified: November 2010

Keywords provided by China Medical University Hospital:
VEGFC
CTTN
miR326
ESCC
NSCLC

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms